Levodopa (L‐dopa) is widely considered as one of the most effective drug constituents in the treatment of Parkinson's disease (PD), but the blood‐brain barrier (BBB) permeability of L‐dopa is <5%, which causes low efficacy. Neuroprotective effects of β‐asarone on 6‐hydroxydopamine (6‐OHDA)‐induced PD rats were demonstrated by our previous studies. Co‐administration of β‐asarone and L‐dopa has not been explored until being investigated on PD rats in this study. PD rats were divided into four groups: untreated, L‐dopa‐treated, β‐asarone‐treated and co‐administered‐treated groups. All of the treatments were administered to the rats twice per day for 30 days. The L‐dopa, dopamine (DA), 3,4‐dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), S100β and neuron‐specific enolase (NSE) levels were subsequently determined. The P‐glycoprotein (P‐gp), zonula occludens‐1 (ZO‐1), claudin‐5, occludin and actin expression was also assessed in cortex. Changes in BBB ultrastructure were observed using transmission electron microscopy. Our results showed that the co‐administered treatment increased levels of L‐dopa, DA, DOPAC and HVA in striatum, and S100β in plasma, but down‐regulated NSE, P‐gp, ZO‐1, occludin, actin and claudin‐5 in cortex. Crevices were observed between capillary endothelial cells at intercellular tight junction of the striatum in co‐administered‐treated group, while the endothelial cells in untreated group were tightly jointing each other. In addition, the correlations of L‐dopa or DA and P‐gp or tight junction proteins respectively were significantly negative in co‐administered‐ and β‐asarone‐treated groups. These findings suggest that co‐administered treatment may enhance the L‐dopa BBB permeability and attenuate brain injury, which may be beneficial to PD treatment.